Loading
A phase 1/2 trial of EB-NK-301 and Fludarabine in advanced solid tumours, run by Beijing Biotech, now recruiting.
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors. ClinicalTrials.gov record last updated 2026-05-15: recruiting. Enrollment is planned at 60 participants. Primary completion is estimated at 2027-02-14. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: EB-NK-301, Fludarabine. Registered primary measures: Incidence of dose-limiting toxicities (DLTs) (CTCAE v5.0); Incidence and severity of treatment-emergent adverse events (AEs); Recommended Phase 2 dose (RP2D) of EB-NK-301.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fludarabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fludarabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/